Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.
Multiple sclerosis is characterized morphologically by the key features demyelination, inflammation, gliosis and axonal damage. In recent years, it has become more evident that axonal damage is the major morphological substrate of permanent clinical disability. In our study, we investigated the occurrence of acute axonal damage determined by immunocytochemistry for amyloid precursor protein (APP) which is produced in neurones and accumulates at sites of recent axon transection or damage. The numbers of APP-positive axons in multiple sclerosis lesions were correlated with the disease duration and course. Most APP-positive axons were detected within the first year after disease onset, but acute axonal damage was also detected to a minor degree in lesions of patients with a disease duration of 10 years and more. This effect was not due to the lack of active demyelinating lesions in the chronic disease stage. Late remyelinated lesions (so-called shadow plaques) did not show signs of axon destruction. The number of inflammatory cells showed a decrease over time similar to that of the number of APP-positive axons. There was a significant correlation between the extent of axon damage and the numbers of CD8-positive cytotoxic T cells and macrophages/microglia. Our results indicate that a putative axon-protective treatment should start as early as possible and include strategies preventing T cell/macrophage-mediated axon destruction and leading to remyelination of axons.
Kuhlmann
Tanja
T
Department of Neuropathology, Charité, Humboldt-Universität, Campus Virchow-Klinikum, Augustenburger Platz 1, D-13353 Berlin, Germany.
Lingfeld
Gueanelle
G
Bitsch
Andreas
A
Schuchardt
Jana
J
Brück
Wolfgang
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D016564:Amyloid beta-Protein Precursor / Q000096:biosynthesis; D001369:Axons / Q000378:metabolism / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors
D016564:Amyloid beta-Protein Precursor; D018696:Neuroprotective Agents